BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder primarily characterized by the co-existence of attentional problems and hyperactivity. Lisdexamfetamine dimesilate (LDX) was authorized for treatment of ADHD in Australia in 2013.
OBJECTIVES: The overall objective of the study is to provide utilization data for LDX in Australia.
METHODS: This is a cross-sectional study which includes longitudinal patient level prescription data(IMS® LRx database) and deidentified patient datafrom a survey among physicians known to treatpatients with ADHD. The study was conducted inan outpatient setting across Australia. Here, data from 01 September 2013 to 31 August 2015 are shown.
RESULTS: Data from 101 patients in the survey and from 1,701 LDX prescriptions in the database for471 patients were analysed. 76% of the patients documented in the survey were male. One patient(1%) was younger than 6 years, 70 patients(69.3%) were between 6 and 17 years. 30 patients(29.7%) were adults. No patient was older than 55years.All patients had a documented diagnosis of ADHD. For all but one patient, ADHD was documented as the main indication for prescribing LDX. The average daily dose (ADD) prescribed by the physicians in the survey was between 10 mg to 140mg, with a mean around 41.9 mg per day. Recommended daily dose of 70 mg was not exceeded in99% of patients in the physician survey. Mean ADD derived from IMS® LRx data was 44.6 mg, with97% within the recommended range.
CONCLUSIONS: Overall, the findings indicate that LDXis prescribed mainly within the label. That is, to the indicated age group and without exceeding the recommended dosage
